林业发展局以合成Kratom化合物为目标,列举了潜在的危险和不受管制的销售。 FDA targets synthetic kratom compound, citing potential dangers and unregulated sales.

美国卫生官员正在对与Kratom有关的产品采取行动,因为行业对不受管制的销售和潜在的健康风险提出投诉。 US health officials are taking action against kratom-related products due to industry complaints over unregulated sales and potential health risks. 林业发展局具体针对的是7-氢氧二硝基苯丙胺,这是一种合成的Kratom,警告说它比吗啡更有力。 The FDA specifically targets 7-hydroxymitragynine, a synthetic form of kratom, warning it could be more potent than morphine. 该机构建议将它列入高度受限药物清单,并向提出未经证实的健康索赔的公司发出警告。 The agency recommends adding it to the list of highly restricted drugs, and has issued warnings to companies making unproven health claims. 镇压的目的是在人们日益关注Kratom的安全和滥用问题的情况下保护消费者。 The crackdown aims to protect consumers amid growing concerns about the safety and abuse of kratom.